Is AVBP or CRON more profitable?

CRON runs the higher net margin — AVBP at 0.00% versus CRON at 30.98%.

ArriVent BioPharma, Inc. (AVBP) vs Cronos Group Inc. (CRON)

A side-by-side comparison of ArriVent BioPharma, Inc. and Cronos Group Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AVBP

ArriVent BioPharma, Inc.

$703M

$15.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

CRON

Cronos Group Inc.

$1.23B

$3.29HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — AVBP vs CRON

growth of $100 · dividends reinvested · last 3y

AVBP +42.3% (+12.5%/yr)CRON +61.7% (+17.4%/yr)CRON compounded faster over this window

AVBP CRON

AVBP vs CRON: by the numbers

•CRON is the larger company ($1.23B vs $703M market cap).
•CRON is profitable (30.98% net margin) while AVBP runs a net loss (0.00%).

Metrics side by side

Valuation

Metric	AVBP	CRON
P/E ratio	N/A	18.14
P/S ratio	N/A	5.45
P/B ratio	1.92	1.15
EV / EBITDA	N/A	28.08
FCF yield	N/A	4.05%

Profitability

Metric	AVBP	CRON
Gross margin	0.00%	36.16%
Operating margin	0.00%	-11.96%
Net margin	0.00%	30.98%
ROE	-44.63%	6.53%
ROIC	-47.96%	1.12%

Growth (annualized)

Metric	AVBP	CRON
Revenue CAGR (5Y)	N/A	31.80%
Total return CAGR (5Y)	N/A	-9.92%

Frequently asked

Is AVBP or CRON more profitable?: CRON runs the higher net margin — AVBP at 0.00% versus CRON at 30.98%.

Go deeper

Full AVBP analysis Full CRON analysis Interactive comparison tool

Dig into the metrics

Cronos P/E ratio ArriVent BioPharma ROE Cronos ROE ArriVent BioPharma operating margin Cronos operating margin ArriVent BioPharma revenue growth Cronos revenue growth ArriVent BioPharma free cash flow Cronos free cash flow

ArriVent BioPharma & Cronos appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.